Evidence map›Paper›PMID 38260254›Full record

ArticlebioRxiv : the preprint server for biology2024

Local delivery of cell surface-targeted immunocytokines programs systemic anti-tumor immunity.

Luciano Santollani, Yiming J Zhang, Laura Maiorino, Joseph R Palmeri, Jordan A Stinson, Lauren R Duhamel, Kashif Qureshi, Jack R Suggs, Owen T Porth, William Pinney and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Luciano SantollaniDepartment of Chemical Engineering, Massachusetts Institute of Technology; Cambridge, MA, USA.
Yiming J ZhangKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge; MA, USA.
Laura MaiorinoKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge; MA, USA.
Joseph R PalmeriDepartment of Chemical Engineering, Massachusetts Institute of Technology; Cambridge, MA, USA.
Jordan A StinsonKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge; MA, USA.
Lauren R DuhamelKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge; MA, USA.
Kashif QureshiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge; MA, USA.
Jack R SuggsDepartment of Chemical Engineering, Massachusetts Institute of Technology; Cambridge, MA, USA.
Owen T PorthKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge; MA, USA.
William PinneyKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge; MA, USA.
Riyam Al MsariKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge; MA, USA.
K Dane WittrupDepartment of Chemical Engineering, Massachusetts Institute of Technology; Cambridge, MA, USA.
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge; MA, USA.
Allen Institute · USHoward Hughes Medical Institute · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9M
Localized immunotherapy using alum-binding therapeuticsR01EB031082 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI IRVINE, DARRELL J, WITTRUP, KARL DANE · 2021 to 2024
$2.1M
NCI NIH HHS P30 CA014051NIBIB NIH HHS R01 EB031082
6 · The paper itself

Abstract

Cytokine therapies are potent immunotherapy agents but exhibit severe dose-limiting toxicities. One strategy to overcome this involves engineering cytokines for intratumoral retention following local delivery. Here, we develop a localized cytokine therapy that elicits profound anti-tumor immunity by engineered targeting to the ubiquitous leukocyte receptor CD45. We designed CD45-targeted immunocytokines (αCD45-Cyt) that, upon injection, decorated the surface of leukocytes in the tumor and tumor-draining lymph node (TDLN) without systemic exposure. αCD45-Cyt therapy eradicated both directly treated tumors and untreated distal lesions in multiple syngeneic mouse tumor models. Mechanistically, αCD45-Cyt triggered prolonged pSTAT signaling and reprogrammed tumor-specific CD8

Identifiers

PMID38260254
PMCPMC10802272
OpenAlexW4390649801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.